Appendix 4: List of Novel Agents

  • Index

Mode of Action Specificity Drugs
Monoclonal antibodies Cold Rituximab, Ofatumumab, Obinutuzumab, Alemtuzumab
Monoclonal antibodies Drug conjugate Brentuximab vedotin, Polatuzumab vedotin
Monoclonal antibodies Bispecific Blinatumomab
Monoclonal antibodies Radioisotope bound Ibritumomab tiuxetan, Tositumomab
B-Cell-Receptor pathway inhibitors BTK Ibrutinib, Ono 4059
B-Cell-receptor pathway inhibitors PI3K Idelalisib, Duvelisib, Copanlisib
B-Cell-receptor pathway inhibitors mTOR Temsirolimus, Everolimus
Immune checkpoint regulators   Nivolumab, Pembrolizumab
Immune modulators   Lenalidomide
HDAC inhibitors   Romidepsin, Belinostat
Antiapoptotic drugs Bcl-2-inhibitors Venetoclax
Others Aurora kinase Inhibitors Alisertib
Others ALK-inhibitors Crizotinib
Newer cytostatics   Bendamustine, Pixantrone

Highlighted (bold): approved in EU for the treatment of lymphoma.

« Previous Page Next Page »

Last update: 01 June 2015